miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas

Zeng, Ailiang; Yin, Jianxin; Wang, Zheng; Zhang, Chuanbao; Li, Rui; Zhang, Zhuoran; Yan, Wei; You, Yongping

doi:10.1080/2162402x.2018.1510277

Cited by 18 publications

(19 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We revealed that tumor purity was strongly associated with clinical and genomic characteristics. Low purity was an independent unfavorable prognostic indicator of OS in GC regardless of age and TNM stage, which consistent with the previous studies in other tumors 4,5,10 …”

Section: Discussionsupporting

confidence: 91%

“…Low purity was an independent unfavorable prognostic indicator of OS in GC regardless of age and TNM stage, which consistent with the previous studies in other tumors. 4,5,10 Genes with higher mutation rate in low-purity group were functionally annotated by DAVID. The most statistically significant annotation enrichments including protein kinase activity and activation of GTPase activity which may promote tumor growth and metastasis and partially explain the unfavorable prognosis in low-purity group.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer

Gong

Zhang

2020

Cancer Medicine

View full text Add to dashboard Cite

Tumor microenvironment (TME) has been illustrated their clinic pathological significance in predicting outcomes and therapeutic efficacy by more and more studies. Tumor purity, which reflects the features of TME, is defined as the proportion of cancer cell in the tumor tissue. However, the current staging and prognostic prediction system in gastric cancer (GC) paid little attention to TME. Therefore, we carried out the study to explore the role of tumor purity in GC. We retrospectively collected the clinical and transcriptomic data from four public data sets (n = 1340), GSE15459 , GSE26253 , GSE62254 , and The Cancer Genome Atlas (TCGA). About 34 GC patients from Fudan University Shanghai Cancer Center (FUSCC) were assigned as an independent validation group. Tumor purity was measured by a computational method. Low tumor purity was associated with unfavorable prognosis, upregulated EMT and stemness pathways, more infiltrating of Tregs, M1 and M2 macrophages and a higher expression level of various immune checkpoints and chemokines recruiting immune suppressive cells. Our study indicates low tumor purity in GC was associated with unfavorable prognosis and immune‐evasion phenotype. Further investigations toward tumor purity in GC may contribute to prognosis prediction and the decision of therapy strategies.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer

Gong

Zhang

2020

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Regarding the clinical implications of our results, our findings about CXCL14 expression in glioma datasets support a view of CXCL14 tagging the most aggressive tumors (IV grade versus other grades), subtypes (mesenchymal and classical versus proneural), regions (leading edge of the tumors and infiltrating tumor areas), and G-CIMP status (NON G-CIMP vs G-CIMP). This last observation in particular may overlap with that, by Zeng and co-authors [31], about a trend of CXCL14 overexpression in IDH wt gliomas vs IDH mutant ones: G-CIMP tumors in fact were closely related to IDH mutation, and a better prognosis characterizes patients carrying them [26,34]. Moreover, G-CIMP subtypes are highly enriched among the proneural subtypes, compared with NON G-CIMP tumors [34].…”

Section: Discussionmentioning

confidence: 81%

“…The role of CXCL14 in cancer is controversial, as it was shown to play either tumor suppressive or tumor supportive roles, depending on the specific tumor type [13,27,28,29,30]. In glioblastoma, however, others and us showed that CXCL14 mRNA expression is enriched in tumor samples [17,31], where this chemokine is likely produced and secreted in the tumor microenvironment by reactive astrocytes [17] or other types of stromal cells [32]. To this regard, it is interesting to notice that, in the samples we tested in the present work, the most abundant expression of CXCL14 was found in cultured astrocytes.…”

Section: Discussionmentioning

confidence: 99%

The Expression of the Chemokine CXCL14 Correlates with Several Aggressive Aspects of Glioblastoma and Promotes Key Properties of Glioblastoma Cells

Fazi

Proserpio

Galardi

et al. 2019

IJMS

View full text Add to dashboard Cite

Glioblastoma (GBM) is a primary brain tumor whose prognosis is inevitably dismal, leading patients to death in about 15 months from diagnosis. Tumor cells in the mass of the neoplasm are in continuous exchange with cells of the stromal microenvironment, through the production of soluble molecules, among which chemokines play prominent roles. CXCL14 is a chemokine with a pro-tumor role in breast and prostate carcinoma, where it is secreted by cancer associated fibroblasts, and contributes to tumor growth and invasion. We previously observed that CXCL14 expression is higher in GBM tissues than in healthy white matter. Here, we study the effects of exogenously supplemented CXCL14 on key tumorigenic properties of human GBM cell lines. We show that CXCL14 enhances the migration ability and the proliferation of U87MG and LN229 GBM cell lines. None of these effects was affected by the use of AMD3100, an inhibitor of CXCR4 receptor, suggesting that the observed CXCL14 effects are not mediated by this receptor. We also provide evidence that CXCL14 enhances the sphere-forming ability of glioblastoma stem cells, considered the initiating cells, and is responsible for tumor onset, growth and recurrence. In support of our in vitro results, we present data from several GBM expression datasets, demonstrating that CXCL14 expression is inversely correlated with overall survival, that it is enriched at the leading edge of the tumors and in infiltrating tumor areas, and it characterizes mesenchymal and NON G-CIMP tumors, known to have a particularly bad prognosis. Overall, our results point to CXCL14 as a protumorigenic chemokine in GBM.

show abstract

“…CTSC was associated with proliferation of colorectal cancer cell [120], but this gene may be responsible for the proliferation of GBM cells. Genes such as ERBB2 [121], PDGFRA [122], PDGFRB [123], ITGA5 [124], AKT1 [125], COL1A1 [126], COL6A1 [127], THBS2 [128], PLOD2 [129], P4HA1 [130], IL10 [131], SPARC [132], IL18 [133], SRPX2 [134], CCL2 [135], PLAT [136], PLAU [137], CXCL12 [138], SFRP2 [139], ANGPT1 [140], CXCL14 [141], TGM2 [142], FSTL1 [143], IGFBP5 [144], IGFBP7 [145], LOX [146], and LOXL1 [147] were diagnosed with the development of GBM. ACTN1, COL4A5 , COL6A2 , LAMB2 , P3H1 , COL15A1 , COL16A1 , PCOLCE2 , PCOLCE , PCSK5 , IK3IP1, MFAP4 , FAM20C , C1QTNF1 , PLXNA3 , and NTNG1 were identified as novel biomarkers for the pathogenesis of GBM.…”

Section: Discussionmentioning

confidence: 99%

Identification of Crucial Candidate Genes and Pathways in Glioblastoma Multiform by Bioinformatics Analysis

Alshabi

Vastrad²,

Shaikh

et al. 2019

Biomolecules

View full text Add to dashboard Cite

The present study aimed to investigate the molecular mechanisms underlying glioblastoma multiform (GBM) and its biomarkers. The differentially expressed genes (DEGs) were diagnosed using the limma software package. The ToppGene (ToppFun) was used to perform pathway and Gene Ontology (GO) enrichment analysis of the DEGs. Protein-protein interaction (PPI) networks, extracted modules, miRNA-target genes regulatory network and TF-target genes regulatory network were used to obtain insight into the actions of DEGs. Survival analysis for DEGs was carried out. A total of 590 DEGs, including 243 up regulated and 347 down regulated genes, were diagnosed between scrambled shRNA expression and Lin7A knock down. The up-regulated genes were enriched in ribosome, mitochondrial translation termination, translation, and peptide biosynthetic process. The down-regulated genes were enriched in focal adhesion, VEGFR3 signaling in lymphatic endothelium, extracellular matrix organization, and extracellular matrix. The current study screened the genes in the PPI network, extracted modules, miRNA-target genes regulatory network, and TF-target genes regulatory network with higher degrees as hub genes, which included NPM1, CUL4A, YIPF1, SHC1, AKT1, VLDLR, RPL14, P3H2, DTNA, FAM126B, RPL34, and MYL5. Survival analysis indicated that the high expression of RPL36A and MRPL35 were predicting longer survival of GBM, while high expression of AP1S1 and AKAP12 were predicting shorter survival of GBM. High expression of RPL36A and AP1S1 were associated with pathogenesis of GBM, while low expression of ALPL was associated with pathogenesis of GBM. In conclusion, the current study diagnosed DEGs between scrambled shRNA expression and Lin7A knock down samples, which could improve our understanding of the molecular mechanisms in the progression of GBM, and these crucial as well as new diagnostic markers might be used as therapeutic targets for GBM.

show abstract

miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas

Cited by 18 publications

References 39 publications

Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer

Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer

The Expression of the Chemokine CXCL14 Correlates with Several Aggressive Aspects of Glioblastoma and Promotes Key Properties of Glioblastoma Cells

Identification of Crucial Candidate Genes and Pathways in Glioblastoma Multiform by Bioinformatics Analysis

Contact Info

Product

Resources

About